Novo Nordisk Exits Internal Parkinson's Unit, Licenses Program to AI Partner Cellular Intelligence
Novo Nordisk shut its internal Parkinson's disease unit and licensed the program to AI-native firm Cellular Intelligence, marking a strategic pivot toward outsourced AI-driven R&D. The move reflects a broader pharma trend: externalizing early-stage discovery to AI partners rather than building capability in-house. NVO shares rose 25% over the past month as investors backed the GLP-1 and AI-outsourcing thesis.
Salvado•